0001494650-24-000010.txt : 20240229
0001494650-24-000010.hdr.sgml : 20240229
20240229160536
ACCESSION NUMBER: 0001494650-24-000010
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240228
FILED AS OF DATE: 20240229
DATE AS OF CHANGE: 20240229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Marino Michael F III
CENTRAL INDEX KEY: 0001502700
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38241
FILM NUMBER: 24703549
MAIL ADDRESS:
STREET 1: C/O NUPATHE, INC.
STREET 2: 227 WASHINGTON STREET, SUITE 200
CITY: CONSHOHOCKEN
STATE: PA
ZIP: 19428
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OptiNose, Inc.
CENTRAL INDEX KEY: 0001494650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 421771610
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1020 STONY HILL ROAD
STREET 2: SUITE 300
CITY: YARDLEY
STATE: PA
ZIP: 19067
BUSINESS PHONE: 267-364-3500
MAIL ADDRESS:
STREET 1: 1020 STONY HILL ROAD
STREET 2: SUITE 300
CITY: YARDLEY
STATE: PA
ZIP: 19067
4
1
wk-form4_1709240704.xml
FORM 4
X0508
4
2024-02-28
0
0001494650
OptiNose, Inc.
OPTN
0001502700
Marino Michael F III
C/O OPTINOSE, INC.
1020 STONY HILL ROAD, SUITE 300
YARDLEY
PA
19067
0
1
0
0
Chief Legal Officer & Corp Sec
0
Common Stock
2024-02-28
4
A
0
280000
0
A
613511
D
Stock Option (Right to Buy)
1.815
2024-02-28
4
A
0
140000
0
A
2034-02-28
Common Stock
140000
140000
D
Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on February 28, 2025, and the balance vests in equal quarterly installments over the remaining three years of the four year period, subject to continued service with the Issuer provided that, in the event certain minimum performance criteria related to the net revenue and operating profit of OptiNose, Inc. are achieved, then any unvested RSUs shall become fully-vested subject to the Executive's continued service through such date. Each RSU represents the right to receive one share of common stock of OptiNose,
Inc.
The option vests and becomes exercisable over a four-year period commencing on February 28, 2024. Twenty-five percent (25%) of the option vests and becomes exercisable on February 28, 2025, and the balance vests
in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.
/s/ Anthony Krick, Attorney-in-Fact
2024-02-29